ZEGALOGUE
Peakdasiglucagon
NDASUBCUTANEOUSSOLUTION
Approved
Mar 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
4/8 — Partial
ZEGALOGUE (dasiglucagon) is glucagon receptor agonists [moa]. First approved in 2021.
Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZEGALOGUE (dasiglucagon) is a subcutaneous glucagon receptor agonist approved in 2021 for the treatment of severe hypoglycemia in patients with diabetes. It works by binding to glucagon receptors to stimulate glucose release from the liver, rapidly raising blood sugar levels in emergency situations.
Peak8.7 years to LOE
As a peak-stage product with strong patent protection through 2035, the brand team is likely focused on market penetration and consolidating market share in the severe hypoglycemia rescue therapy segment.
Mechanism of Action
Glucagon Receptor Agonists
Pharmacologic Class:
Antihypoglycemic Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents
Started Sep 2024
38 enrolled
Diabetes Mellitus, Type 1
A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D
Started May 2023
8 enrolled
HypoglycemiaType 1 Diabetes
Career Relevance
Working on ZEGALOGUE offers the opportunity to develop expertise in the specialized hypoglycemia management space with a differentiated rescue therapy. The peak-stage product with strong patent protection provides stable, strategic commercial roles focused on market penetration and provider education rather than launch activity.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.